{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T19:30:37Z","timestamp":1776713437904,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T00:00:00Z","timestamp":1465430400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s10157-016-1289-1","type":"journal-article","created":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T03:25:05Z","timestamp":1465442705000},"page":"203-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells"],"prefix":"10.1007","volume":"21","author":[{"given":"Lucia","family":"de Stephanis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bonon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Varani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Gaf\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Pinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Pema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Somlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Boletta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Aguiari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,9]]},"reference":[{"key":"1289_CR1","doi-asserted-by":"crossref","unstructured":"Cornec-Le Gall E, et al. Genetics and pathogenesis of autosomal dominant polycystic kidney disease: 20\u00a0years on. Hum Mutat. 2014; 35:1393\u20131406.","DOI":"10.1002\/humu.22708"},{"key":"1289_CR2","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1172\/JCI72272","volume":"124","author":"PC Harris","year":"2014","unstructured":"Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest. 2014;124:2315\u201324.","journal-title":"J Clin Invest."},{"key":"1289_CR3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","volume":"363","author":"AL Serra","year":"2010","unstructured":"Serra AL, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363:820\u20139.","journal-title":"N Engl J Med"},{"key":"1289_CR4","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","volume":"363","author":"G Walz","year":"2010","unstructured":"Walz G, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363:830\u201340.","journal-title":"N Engl J Med"},{"key":"1289_CR5","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"},{"key":"1289_CR6","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","volume":"382","author":"A Caroli","year":"2013","unstructured":"Caroli A, et al. ALADIN study group: effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet. 2013;382:1485\u201395.","journal-title":"Lancet"},{"key":"1289_CR7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000368244","volume":"128","author":"C Riella","year":"2014","unstructured":"Riella C, Czarnecki PG, Steinman TI. Therapeutic advances in the treatment of polycystic kidney disease. Nephron Clin Pract. 2014;128:297\u2013302.","journal-title":"Nephron Clin Pract."},{"key":"1289_CR8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10157-015-1086-2","volume":"19","author":"S Muto","year":"2015","unstructured":"Muto S, et al. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. 2015;19:867\u201377.","journal-title":"Clin Exp Nephrol."},{"key":"1289_CR9","doi-asserted-by":"crossref","first-page":"382","DOI":"10.7326\/0003-4819-159-6-201309170-00004","volume":"17","author":"KF Erickson","year":"2013","unstructured":"Erickson KF, Chertow GM, Goldhaber-Fiebert JD. Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease. Ann Intern Med. 2013;17:382\u20139.","journal-title":"Ann Intern Med"},{"key":"1289_CR10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/CEOR.S76269","volume":"7","author":"SM Brunelli","year":"2015","unstructured":"Brunelli SM, et al. End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases. Clinicoecon Outcomes Res. 2015;7:65\u201372.","journal-title":"Clinicoecon Outcomes Res."},{"key":"1289_CR11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000346812","volume":"37","author":"G Aguiari","year":"2013","unstructured":"Aguiari G, Catizone L, Del Senno L. Multidrug therapy for polycystic kidney disease: a review and perspective. Am J Nephrol. 2013;37:175\u201382.","journal-title":"Am J Nephrol"},{"key":"1289_CR12","doi-asserted-by":"crossref","first-page":"F397","DOI":"10.1152\/ajprenal.00310.2002","volume":"285","author":"M Loghman-Adham","year":"2003","unstructured":"Loghman-Adham M, et al. Immortalized epithelial cells from human autosomal polycystic kidney cysts. Am. J. Physiol. Renal Physiol. 2003;285:F397\u2013412.","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"11","key":"1289_CR13","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/hmg\/ddn039","volume":"17","author":"S Shibazaki","year":"2008","unstructured":"Shibazaki S, et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet. 2008;17(11):1505\u201316.","journal-title":"Hum Mol Genet"},{"key":"1289_CR14","doi-asserted-by":"crossref","first-page":"e12719","DOI":"10.1371\/journal.pone.0012719","volume":"5","author":"C Wodarczyk","year":"2010","unstructured":"Wodarczyk C, et al. Nephrocystin-1 forms a complex with polycystin-1 via a polyproline motif\/SH3 domain interaction and regulates the apoptotic response in mammals. PLoS One. 2010;5:e12719.","journal-title":"PLoS One"},{"key":"1289_CR15","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00109-012-0902-3","volume":"90","author":"G Aguiari","year":"2012","unstructured":"Aguiari G, et al. Polycystin-1 regulates amphiregulin expression through CREB and AP1 signalling: implications in ADPKD cell proliferation. J Mol Med (Berl). 2012;90:1267\u201382.","journal-title":"J Mol Med (Berl)."},{"key":"1289_CR16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1164\/rccm.200506-869OC","volume":"173","author":"K Varani","year":"2006","unstructured":"Varani K, et al. Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:398\u2013406.","journal-title":"Am J Respir Crit Care Med"},{"key":"1289_CR17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bbadis.2009.03.001","volume":"1792","author":"G Aguiari","year":"2009","unstructured":"Aguiari G, et al. Deficiency of polycystic kidney disease-1 gene (PKD1) expression increases A(3) adenosine receptors in human renal cells: implications for cAMP-dependent signalling and proliferation of PKD1-mutated cystic cells. Biochim Biophys Acta. 2009;1792:531\u201340.","journal-title":"Biochim Biophys Acta"},{"key":"1289_CR18","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1681\/ASN.2008030259","volume":"19","author":"SJ Leuenroth","year":"2008","unstructured":"Leuenroth SJ, et al. Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol. 2008;19:1659\u201362.","journal-title":"J Am Soc Nephrol"},{"key":"1289_CR19","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","volume":"103","author":"JM Shillingford","year":"2006","unstructured":"Shillingford JM, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA. 2006;103:5466\u201371.","journal-title":"Proc Natl Acad Sci USA."},{"key":"1289_CR20","doi-asserted-by":"crossref","first-page":"F1193","DOI":"10.1152\/ajprenal.00419.2010","volume":"300","author":"WN Leonhard","year":"2011","unstructured":"Leonhard WN, et al. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol. 2011;300:F1193\u2013202.","journal-title":"Am J Physiol Renal Physiol."},{"issue":"2","key":"1289_CR21","doi-asserted-by":"crossref","first-page":"e32195","DOI":"10.1371\/journal.pone.0032195","volume":"7","author":"LM Zhong","year":"2012","unstructured":"Zhong LM, et al. Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells. PLoS One. 2012;7(2):e32195.","journal-title":"PLoS One"},{"key":"1289_CR22","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","volume":"63","author":"T Yamaguchi","year":"2003","unstructured":"Yamaguchi T, et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int. 2003;63:1983\u201394.","journal-title":"Kidney Int"},{"issue":"6","key":"1289_CR23","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1681\/ASN.2004090800","volume":"17","author":"S Omori","year":"2006","unstructured":"Omori S, et al. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol. 2006;17(6):1604\u201314.","journal-title":"J Am Soc Nephrol"},{"key":"1289_CR24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1681\/ASN.2013121312","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp K, et al. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol. 2015;26:39\u201347.","journal-title":"J Am Soc Nephrol"},{"key":"1289_CR25","first-page":"1591","volume":"466","author":"D Mekahli","year":"2014","unstructured":"Mekahli D, et al. Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin. Pflugers Arch. 2014;466:1591\u2013604.","journal-title":"Pflugers Arch"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1289-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-016-1289-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1289-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1289-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T15:59:53Z","timestamp":1498319993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-016-1289-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,9]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["1289"],"URL":"https:\/\/doi.org\/10.1007\/s10157-016-1289-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,9]]}}}